Cambrex Zenara Presenting at the 5th Annual Smoking Cessation Conference
Zam Shabeer Thahir, Commercial Coordinator, Zenara Pharma
+91 (0) 40 2726 0848
East Rutherford, NJ and London, UK – Cambrex Corporation’s (NYSE: CBM, "Cambrex") Director of Cambrex Zenara, Mr. Arun Narayan, will be presenting at the 5th Annual Smoking Cessation Conference in London. The two day conference, being held January 27-28, 2011 at the Thistle City Barbican Hotel, will feature industry experts in smoking cessation therapies, challenges and control policies.
Mr. Narayan’s presentation on Friday, January 28, 2011 is entitled Tobacco use, smoking cessation and the growing role of NRT in developing countries. The presentation will cover topics related to smoking cessation, including the growing need for cessation in developing countries and governmental efforts to control use of tobacco in BRIC markets to the role of cost effective Nicotine Replacement Therapy (NRT) products.
According to Mr. Narayan, “We are excited to present for the second time at the Smoking Cessation Conference. This conference provides Cambrex Zenara an excellent audience of NGOs, government organizations, heath care providers and other companies with a commercial interest in smoking cessation and NRT. In addition, this conference provides a platform to discuss the latest smoking cessation therapies, innovations, and tobacco control policies.”
Cambrex Zenara provides high quality and competitively priced pharmaceutical drug product, formulation, development and manufacturing capabilities designed to accelerate commercialization of finished drug products for the pharmaceutical industry with specific expertise in NRT. In December 2010, Cambrex Zenara began supplying an NRT product to support a commercial launch in the Indian market.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.